Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles
We compared the differential expression of 15 markers in PTCL (Peripheral T-cell lymphoma) subtypes and T-CUS (T-cell clones of uncertain significance), and summarized the specific immunophenotype profiles of each subtype and its impact on prognosis. PD-1 and CD10 are diagnostic markers for AITL (an...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1008695/full |
| _version_ | 1811189648976773120 |
|---|---|
| author | Qiyao Pu Qiyao Pu Jie Qiao Jie Qiao Yuke Liu Yuke Liu Xueyan Cao Ran Tan Ran Tan Dongyao Yan Dongyao Yan Xiaoqian Wang Xiaoqian Wang Jiwei Li Baohong Yue Baohong Yue Baohong Yue |
| author_facet | Qiyao Pu Qiyao Pu Jie Qiao Jie Qiao Yuke Liu Yuke Liu Xueyan Cao Ran Tan Ran Tan Dongyao Yan Dongyao Yan Xiaoqian Wang Xiaoqian Wang Jiwei Li Baohong Yue Baohong Yue Baohong Yue |
| author_sort | Qiyao Pu |
| collection | DOAJ |
| description | We compared the differential expression of 15 markers in PTCL (Peripheral T-cell lymphoma) subtypes and T-CUS (T-cell clones of uncertain significance), and summarized the specific immunophenotype profiles of each subtype and its impact on prognosis. PD-1 and CD10 are diagnostic markers for AITL (angioimmunoblastic T-cell lymphoma). To avoid confusion with T-CUS of benign clones, it is recommended to define AITL as bounded by PD-1+%>38.01 and/or CD10+%>7.46. T cell-derived ENKTL-N (extranodal NKT cell lymphoma) specifically expresses CD56. ALCL (anaplastic large cell lymphoma) characteristically expresses CD30 and HLA-DR. PTCL-NOS (peripheral T-cell lymphoma unspecified) still lacks a relatively specific phenotype and is prone to loss of basic lineage markers CD3, CD5, and CD7. The determination of T-CUS can be verified by the overall assessment of the bone marrow and a certain period of follow-up. The clustering results showed that the expression of 8 specific markers was significantly different among the 5 groups, suggesting that a combination of related markers can be analyzed in the identification of PTCLs subtypes. The study explores the advantages of TRBC1 combined with CD45RA/CD45RO in detecting T cell clonality, which can efficiently and sensitively analyze multiple target T cell populations at the same time. The sensitivity of PB to replace BM to monitor the tumor burden or MRD (minimal residual disease) of PTCLs is as high as 85.71%, which can relieve the huge pressure of clinical sampling and improve patient compliance. CD7, CD38, and Ki-67 are prognostic indicators for AITL. CD3 and CD8 on PTCL-NOS, and CD56 and HLA-DR on ENKTL-N have prognostic role. This study supports and validates the current classification of PTCL subtypes and establishes an immunophenotypic profile that can be used for precise diagnosis. The important clinical value of PTCLs immunophenotype in routine classification diagnosis, clonality confirmation, prognosis prediction, and treatment target selection was emphasized. |
| first_indexed | 2024-04-11T14:38:04Z |
| format | Article |
| id | doaj.art-0751a0f74300480187bf6969baf1e69b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T14:38:04Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-0751a0f74300480187bf6969baf1e69b2022-12-22T04:18:12ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-11-011310.3389/fimmu.2022.10086951008695Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profilesQiyao Pu0Qiyao Pu1Jie Qiao2Jie Qiao3Yuke Liu4Yuke Liu5Xueyan Cao6Ran Tan7Ran Tan8Dongyao Yan9Dongyao Yan10Xiaoqian Wang11Xiaoqian Wang12Jiwei Li13Baohong Yue14Baohong Yue15Baohong Yue16Department of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaKey Clinical Laboratory of Henan Province, Zhengzhou, Henan, ChinaDepartment of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaKey Clinical Laboratory of Henan Province, Zhengzhou, Henan, ChinaDepartment of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaKey Clinical Laboratory of Henan Province, Zhengzhou, Henan, ChinaSchool of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, ChinaDepartment of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaKey Clinical Laboratory of Henan Province, Zhengzhou, Henan, ChinaDepartment of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaKey Clinical Laboratory of Henan Province, Zhengzhou, Henan, ChinaDepartment of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaKey Clinical Laboratory of Henan Province, Zhengzhou, Henan, ChinaDepartment of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaDepartment of Laboratory Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaKey Clinical Laboratory of Henan Province, Zhengzhou, Henan, ChinaFaculty of Laboratory Medicine, Zhengzhou University, Zhengzhou, Henan, ChinaWe compared the differential expression of 15 markers in PTCL (Peripheral T-cell lymphoma) subtypes and T-CUS (T-cell clones of uncertain significance), and summarized the specific immunophenotype profiles of each subtype and its impact on prognosis. PD-1 and CD10 are diagnostic markers for AITL (angioimmunoblastic T-cell lymphoma). To avoid confusion with T-CUS of benign clones, it is recommended to define AITL as bounded by PD-1+%>38.01 and/or CD10+%>7.46. T cell-derived ENKTL-N (extranodal NKT cell lymphoma) specifically expresses CD56. ALCL (anaplastic large cell lymphoma) characteristically expresses CD30 and HLA-DR. PTCL-NOS (peripheral T-cell lymphoma unspecified) still lacks a relatively specific phenotype and is prone to loss of basic lineage markers CD3, CD5, and CD7. The determination of T-CUS can be verified by the overall assessment of the bone marrow and a certain period of follow-up. The clustering results showed that the expression of 8 specific markers was significantly different among the 5 groups, suggesting that a combination of related markers can be analyzed in the identification of PTCLs subtypes. The study explores the advantages of TRBC1 combined with CD45RA/CD45RO in detecting T cell clonality, which can efficiently and sensitively analyze multiple target T cell populations at the same time. The sensitivity of PB to replace BM to monitor the tumor burden or MRD (minimal residual disease) of PTCLs is as high as 85.71%, which can relieve the huge pressure of clinical sampling and improve patient compliance. CD7, CD38, and Ki-67 are prognostic indicators for AITL. CD3 and CD8 on PTCL-NOS, and CD56 and HLA-DR on ENKTL-N have prognostic role. This study supports and validates the current classification of PTCL subtypes and establishes an immunophenotypic profile that can be used for precise diagnosis. The important clinical value of PTCLs immunophenotype in routine classification diagnosis, clonality confirmation, prognosis prediction, and treatment target selection was emphasized.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1008695/fullperipheral T-cell lymphomaFCM immunophenotypeAITCLT-CUSdifferential diagnosisprognostic marker |
| spellingShingle | Qiyao Pu Qiyao Pu Jie Qiao Jie Qiao Yuke Liu Yuke Liu Xueyan Cao Ran Tan Ran Tan Dongyao Yan Dongyao Yan Xiaoqian Wang Xiaoqian Wang Jiwei Li Baohong Yue Baohong Yue Baohong Yue Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles Frontiers in Immunology peripheral T-cell lymphoma FCM immunophenotype AITCL T-CUS differential diagnosis prognostic marker |
| title | Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles |
| title_full | Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles |
| title_fullStr | Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles |
| title_full_unstemmed | Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles |
| title_short | Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles |
| title_sort | differential diagnosis and identification of prognostic markers for peripheral t cell lymphoma subtypes based on flow cytometry immunophenotype profiles |
| topic | peripheral T-cell lymphoma FCM immunophenotype AITCL T-CUS differential diagnosis prognostic marker |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1008695/full |
| work_keys_str_mv | AT qiyaopu differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT qiyaopu differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT jieqiao differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT jieqiao differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT yukeliu differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT yukeliu differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT xueyancao differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT rantan differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT rantan differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT dongyaoyan differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT dongyaoyan differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT xiaoqianwang differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT xiaoqianwang differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT jiweili differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT baohongyue differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT baohongyue differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles AT baohongyue differentialdiagnosisandidentificationofprognosticmarkersforperipheraltcelllymphomasubtypesbasedonflowcytometryimmunophenotypeprofiles |